Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Outperform at SVB Leerink

SVB Leerink upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) from a market perform rating to an outperform rating in a report published on Wednesday morning, PriceTargets.com reports. SVB Leerink also issued estimates for Arrowhead Pharmaceuticals’ Q2 2023 earnings at ($0.02) EPS, Q3 2023 earnings at ($0.02) EPS, Q4 2023 earnings at $0.33 EPS, […]

Related Keywords

,Piper Sandler ,Adeoyey Olukotun ,News Ratings For Arrowhead Pharmaceuticals Daily ,Arrowhead Pharmaceuticals ,Arrowhead Pharmaceuticals Company Profile ,Analyst Recommendations For Arrowhead Pharmaceuticals ,Securities Exchange Commission ,Raymond James Associates ,Arrowhead Pharmaceuticals Stock Down ,Nasdaq ,Exchange Traded Concepts ,Stonnington Group ,Insider Activity At Arrowhead Pharmaceuticals ,Arrowhead Pharmaceuticals Inc ,Allspring Global Investments Holdings ,Get Rating ,Moderate Buy ,Pharmaceuticals Stock Down ,Director Adeoye ,Exchange Commission ,Director Douglas ,Global Investments Holdings ,Traded Concepts ,Arrowhead Pharmaceuticals Daily ,Nasdaq Arwr ,Arwr ,Medical ,Upgrade ,Svb Leerink Llc ,